Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

Oculis · NCT07548632

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
160
US sites recruiting
12
Study start
April 16, 2026
Record last updated
August 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Being studied: Artificial Tear Run-in; licaminlimab; Vehicle of licaminlimab

Conditions: Dry Eye Disease (DED)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Physician diagnosis of Dry Eye Disease in the past 6 months
  • Use of over-the-counter tears
  • Must agree to genotype testing

Key Exclusion Criteria

  • Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.

Recruiting US locations

Study contacts (from the official record)

  • Oculis Chief Development Officer · 617 928 5886 · info@oculis.com
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease (NCT07548632) | Bored Studies